Evidence map›Paper›PMID 27354930›Full record

ArticleBioResearch open access2016

Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation.

Justine Tanjaya, Yulong Zhang, Soonchul Lee, Jiayu Shi, Eric Chen, Pia Ang, Xinli Zhang, Sotirios Tetradis, Kang Ting, Benjamin Wu and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioResearch open access, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. NELL-1: role and mechanisms in disease pathogenesis and development.Frontiers in cell and developmental biology · 2026
    Review
  2. Role of NEL‑like molecule‑1 in osteogenesis/chondrogenesis (Review).International journal of molecular medicine · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Justine TanjayaDivision of Growth and Development and the Section of Orthodontics, School of Dentistry, University of California , Los Angeles, Los Angeles, California.
Yulong ZhangDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, California.; Department of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, California.
Soonchul LeeDepartment of Orthopaedic Surgery, CHA Bundang Medical Center, CHA University, Pocheon, South Korea.; Department of Orthopaedic Surgery and the Orthopaedic Hospital Research Center, University of California, Los Angeles, Los Angeles, California.
Jiayu ShiDivision of Growth and Development and the Section of Orthodontics, School of Dentistry, University of California , Los Angeles, Los Angeles, California.
Eric ChenDivision of Growth and Development and the Section of Orthodontics, School of Dentistry, University of California , Los Angeles, Los Angeles, California.
Pia AngDivision of Growth and Development and the Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, California.; Department of Orthopaedic Surgery and the Orthopaedic Hospital Research Center, University of California, Los Angeles, Los Angeles, California.
Xinli ZhangDivision of Growth and Development and the Section of Orthodontics, School of Dentistry, University of California , Los Angeles, Los Angeles, California.
Sotirios TetradisSection of Oral and Maxillofacial Radiology, School of Dentistry, University of California , Los Angeles, Los Angeles, California.
Kang TingDivision of Growth and Development and the Section of Orthodontics, School of Dentistry, University of California, Los Angeles, Los Angeles, California.; Department of Orthopaedic Surgery and the Orthopaedic Hospital Research Center, University of California, Los Angeles, Los Angeles, California.
Benjamin WuDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, California.; Department of Materials Science and Engineering, University of California, Los Angeles, Los Angeles, California.
Chia SooDepartment of Orthopaedic Surgery and the Orthopaedic Hospital Research Center, University of California, Los Angeles, Los Angeles, California.; Division of Plastic and Reconstructive Surgery, Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Jin Hee KwakDivision of Growth and Development and the Section of Orthodontics, School of Dentistry, University of California , Los Angeles, Los Angeles, California.
University of California, Los Angeles · US

Funding

NELL-1 Systemic Therapy for OsteoporosisR01AR066782 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EASLEY, JEREMIAH, TING, KANG · 2014 to 2018
$2.0M
Medical Research Council MC_U117533887NIAMS NIH HHS R01 AR066782
6 · The paper itself

Abstract

Systemically delivered NEL-like molecule-1 (NELL-1), a potent pro-osteogenic protein, promotes bone formation in healthy and osteoporotic mouse models. PEGylation of NELL-1 (NELL-PEG) increases the half-life of the protein in a mouse model without compromising its osteogenic potential, thereby improving its pharmacokinetics upon systemic delivery. This study consists of a twofold approach: a biodistribution test and an in vivo osteogenic potential test. The biodistribution test compared two commonly used administration methods for drug delivery other than intravenous-intraperitoneal (IP) and subcutaneous (SC)-to examine NELL-PEG biodistribution in mice. Compared to a single-dose SC injection (1.25 mg/kg), a single-dose IP administration yielded a higher protein uptake in the targeted bone sites. When the IP injection dose was doubled to 2.5 mg/kg, the protein remained in the femurs, tibias, and vertebrae for up to 72 h. Next, based on the results of the biodistribution study, IP administration was selected to further investigate the in vivo osteogenic effects of weekly NELL-PEG injection (q7d). In vivo, the IP administered NELL-PEG group showed significantly greater bone mineral density, bone volume fraction, and trabecular bone formation in the targeted bone sites compared to the phosphate-buffered saline control. In summary, weekly NELL-PEG injection via IP administration successfully enhanced the overall bone quality. These findings demonstrate that systemic delivery of NELL-PEG via IP administration may serve as an effective osteogenic therapy for preventing and treating osteoporosis.

Indexed as

biodistributionbone formationintraperitoneal administrationosteoporosisPEGylated NELL-1

Identifiers

PMID27354930
PMCPMC4921932
OpenAlexW2205679627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.